A “triple whammy” in adenocarcinoma lung

Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), is useful in the treatment of non-small cell lung cancer who show resistance to first-generation EGFR-TKIs and harbor T790M mutation. Acquisition of resistance to osimertinib due to sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Patro, Mahismita, Gothi, Dipti, Vaidya, Sameer, Sah, Ram Babu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625246/
https://www.ncbi.nlm.nih.gov/pubmed/31290421
http://dx.doi.org/10.4103/lungindia.lungindia_212_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625246/
https://www.ncbi.nlm.nih.gov/pubmed/31290421
http://dx.doi.org/10.4103/lungindia.lungindia_212_18

Ejemplares similares